Share this page

Latest news


Latest News Gfatm awards up to $1.3 billion for malaria projects

NEWS: The Global Fund Awards up to $1.3 Billion for Malaria Projects

12 November 2009

London, 12 November 2009: The Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 17 out of 31 malaria proposals, a total of $609 million over two years and up to $1.3 billion over five years.

Partners in the Roll Back Malaria (RBM) Harmonization Working Group and other RBM mechanisms supported countries during the application process.  Ten out of 12 Affordable Medicines Facility for Malaria (AMFm) proposals were also approved in this round which will improve access to artemisinin based combination therapies (ACTs)  - the most effective treatments today for malaria .  

"Countries should continue be encouraged by this result,” said Dr Awa Marie Coll-Seck , Executive Director of RBM Partnership. “Substantial resources are being made available to help countries achieve impact against malaria. We are delighted with this announcement and will work even harder to support those countries who did not benefit from this Round.”

She added: “The Global Fund continues to be the greatest financier of malaria control and has taken on new and important initiatives, such as the AMFm, which will boost access to life saving drugs."

Among those approved by the Global Fund is a proposal to expand malaria control across all those at risk from the disease in Cameroon.  Malaria Consortium’s partner and affiliate, the Cameroon Coalition Against Malaria (CCAM), will manage the advocacy component of this project.

Overall, the Board made a two-year commitment of US$2.4 billion in Round 9 for all three diseases which could increase to US$ 7 billion over five years. The next round of grants will be launched in May 2010.  Round 10 will  be considered for approval at a GF Board meeting to be held some time between November 2010 and January 2011.

To view the Global Fund press release click here

For more information, please contact Diana Thomas, [email protected]



Click here for news archive »